Eye drop with anti-cornea rebirth blood vessel function and preparation method thereof

Abstract

The invention relates to eye drops adopting arteannuinum succinate as the raw material for treating corneal neovascularization and a preparation method thereof. The arteannuinum succinate eye drops can be produced by adopting raw materials in the following parts by weight: 0.0096 to 0.0384 parts of arteannuinum succinate, 1.0032 to 12.028 parts of acid component in buffer solution, 0.106 to 18.0477 parts of alkaline component in buffer solution, 1.0 to 35.0 parts of thickener, 2.0 to 4.72 parts of isotonic reagent and 0.01 to 0.02 parts of antiseptics. The preparation method for the eye drops comprises the following steps: dissolving the arteannuinum succinate with NaHCO3, filtering and sterilizing for later use; dissolving appropriate amount of buffer solution, isotonic reagent and thickener into distilled water, sterilizing for 20 minutes with 100 to 120 DEG C high pressure to obtaining treatment fluid, and cooling the treatment fluid to room temperature for stand to by use; preparing the antiseptics with distilled water into high concentration storage solution, filtering, sterilizing and subpackaging for later use; in aseptic condition, adding the arteannuinum succinate into the treatment fluid according to the ratio of adding 16 to 66 Mul of arteannuinum succinate into 100 ml treatment fluid, uniformly blending, and at the same time, adding the antiseptics into the buffer solution according to the ratio of adding 50 to 100 Mul of antiseptics into 100 ml buffer solution, and subpackaging and producing eye drops in different specifications; preferably, the package per bottle is 0.5 ml.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, and relates to a medicine for treating corneal neovascularization, in particular to artesunate eye drops using artesunate as a raw material and a preparation method thereof. Background technique [0002] Normal corneal tissue has no blood vessels, and the pericorneal tissue terminates at the limbus and forms a network of blood vessels through which nutrients diffuse into the cornea. The avascularity of the cornea is one of the important factors in maintaining its transparency and serving as an important refractive medium. Corneal neovascularization (CNV) is formed when capillaries grow from the limbus into the cornea under conditions such as wearing contact lenses, eye trauma or chemical injury, infection, previous surgery history, trichiasis, and immune eye disease. CNV destroys the normal microenvironment of the cornea, leading to the disappearance of anterior segment-related immune ...

AI Technical Summary

Problems solved by technology

[0005] The Chinese patent literature with the authorized announcement number CN1208061C discloses a kind of artesunate microsphere injection, which uses slow-release polymer to grind artesunate to prepare microsphere injection, which is mainly used for the treatment of tumor-related vascular hyperplasia and vascular hyperplasia caused by other diseases, but the microsphere injection is not suitable for the treatment of ocular surface vascular hyperplasia

The reason is: on the one hand, the treatment of ocular surface diseases is often based on eye drops that are easy to use and popular with patients. This drug is an injection drug, so it is inconvenient to use in terms of dosage form

In addition, the polymer in the microsphere injection degrades into water and carbon dioxide after slow drug release. Whether the released carbon dioxide affects the pH value of the ocular surface and other physiological indicators, and whether it affects the recovery of the damaged cornea remains to be discussed. Artesunate preparations in the patent literature are not suitable for the treatment of corneal neovascularization

Images